Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.

The post Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark appeared first on Investor’s Business Daily.